Skip to content
  1. EMEA Innovative Medicine /
  2. About us /
  3. Our responsibilities /
  4. Sustainability /
  5. Medicines supply

Medicines supply

At Johnson & Johnson, our policy advocacy focuses on supporting strong and resilient global supply chains for medical goods to ensure access for patients, providers, and consumers, even during major public health threats. Our principles are centred around strengthening supply chain diversity and resiliency, safeguarding patient access through the free flow of medical goods, supporting and preparing the manufacturing workforce, and maintaining strategic stockpiles with appropriate products and volumes. We advocate for these policy measures to create efficient supply chains that prioritize patient access, support the healthcare workforce, and enable an effective response to public health challenges. By championing these principles, we aim to ensure uninterrupted access to essential medical goods when they are most needed.

To safeguard medicine supply for all patients, we need a coordinated EU approach. EU-wide coordination and harmonization must replace today’s multitude of national approaches. Coordination enables flexible resource allocation to meet patients’ needs. Watch to find out more.

J&J - Critical Medicines Act - Building Resilient Supply Chains Across the EU.mp4
J&J - Critical Medicines Act - Building Resilient Supply Chains Across the EU.mp4

Regulatory flexibilities are needed to create more agile and resilient supply chains. Watch to find out more.

J&J - Critical Medicines Act - Regulatory Flexibility.mp4
J&J - Critical Medicines Act - Regulatory Flexibility.mp4

To find out more about the importance of global supply chains, Watch Leveraging supply chains to avoid medicine shortages.

leveraging-supply-chains-to-avoid-medicine-shortages-long-2.png
leveraging-supply-chains-to-avoid-medicine-shortages-long-2.png

CP-516647
May 2025